Therapeutic Effect of Cyclin-Dependent Kinase 4/6 Inhibitor on Dermal Fibrosis in Murine Models of Systemic Sclerosis

Researchers examined whether the inhibition of cell cycle with cyclin-dependent kinase (CDK) 4/6 inhibitor suppressed fibroblast proliferation and the differentiation into myofibroblasts, and the therapeutic effect of a CDK4/6 inhibitor on dermal fibrosis in murine models of systemic sclerosis in monotherapy or in combination with TGF-β receptor inhibitor.